Headquartered in Gaithersburg, MD Fiscal year ends December NASDAQ: NVAX novavax.com
Novavax, Inc. (Nasdaq: NVAX) is a biotechnology company focused on developing and commercializing vaccines using its proprietary protein-based nanoparticle technology and Matrix-M adjuvant platform. The company's marketed products include Nuvaxovid, a COVID-19 vaccine, and it contributes Matrix-M adjuvant to the R21/Matrix-M malaria vaccine. Novavax's corporate strategy centers on three pillars: partnering its technology through licensing agreements (most notably a co-exclusive licensing agreement with Sanofi for COVID-19 and combination vaccines), pursuing targeted and capital-efficient R&D innovation (including a C. difficile vaccine candidate), and maintaining a lean operating model. The company generates revenue from direct product sales, supply sales to license partners, licensing fees, milestones, royalties, and R&D reimbursements. Its Matrix-M adjuvant platform is being evaluated by multiple partners across infectious disease and oncology targets, creating additional potential licensing opportunities. Updated
Shrugging off a valuation downgrade, Moderna (NASDAQ:MRNA | MRNA Price Prediction) is climbing as investors weigh strong cancer vaccine data against a share price that already reflects big expectations. Moderna stock stands…
Vaccine stocks are under heavy pressure, and the smallest name in the group is taking the heaviest losses. Novavax (NASDAQ:NVAX) stock is down 12% to $11.23 in afternoon trading, leading the slide…
A protein-vaccine developer with no fresh catalyst just posted a double-digit gain that dwarfs what Moderna and Merck managed in the same session, and the explanation reveals something uncomfortable about how this…
A plague headline out of Siberia lifted vaccine stocks, and the agencies closest to the case have since described the risk as low. That reversal in sentiment lands hardest on Novavax (NASDAQ:NVAX),…
Sanofi just handed Novavax a commercial lifeline for the fall vaccination season, and the stock is reacting in a way that leaves Moderna and BioNTech looking like bystanders. The real question is…
Cancer vaccine momentum is doing the work for Moderna (NASDAQ:MRNA | MRNA Price Prediction) once again on Thursday, extending one of the sharpest one-month runs in large-cap biotech this year without a…
Retail traders are piling into Novavax on cancer-vaccine speculation, but the move that actually changed the company's business model happened quietly last week and has nothing to do with oncology.
Moderna (NASDAQ:MRNA | MRNA Price Prediction) stock is jumping again. Shares are up 9% today, trading near $57 in the Tuesday afternoon session. That extends a remarkable 2026 run for the mRNA…
Shares of Moderna (NASDAQ:MRNA | MRNA Price Prediction) are up roughly 6% in Monday morning trading, changing hands near $57.52 after Friday’s close of $54.35. The intraday move extends what has already…
The COVID-19 vaccine boom made fortunes almost overnight—and destroyed them just as fast. Moderna (NASDAQ: MRNA | MRNA Price Prediction) has fallen 58.2% over five years. BioNTech (NASDAQ: BNTX) is down 10.9%…
With the pandemic largely in the rear-view mirror, COVID-19 vaccine winner Novavax has seen shares fall. Yet, analysts have high hopes for the stock.
These are five stocks for aggressive investors looking to get share count leverage on companies that have sizable upside potential. While not suited for all investors, they are not penny stocks with…
These are five stocks for aggressive investors looking to get share count leverage on companies that have sizable upside potential. While not suited for all investors, they are not penny stocks with…
Thursday's top analyst upgrades and downgrades included Bumble, Coupang, Datadog, Dish Network, DraftKings, Eli Lilly, International Flavors & Fragrances, LivePerson, Novavax, Nvidia, Qualcomm and Rivian Automotive.
These are five stocks for aggressive investors looking to get share count leverage on companies that have sizable upside potential. While not suited for all investors, they are not penny stocks with…
Novavax, Inc. (Nasdaq: NVAX) is a biotechnology company focused on developing and commercializing vaccines using its proprietary protein-based nanoparticle technology and Matrix-M adjuvant platform.
The Wall Street consensus 12-month price target for NVAX is $14.22.
